A clinical trial of Ampligen in combination with atezolizumab for the treatment of advanced pancreatic cancer
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2018
Price : $35 *
At a glance
- Drugs Atezolizumab (Primary) ; Rintatolimod (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 15 Nov 2018 According to a Hemispherx Biopharma media release, Dr. K. Klute, PI, the University of Nebraska Medical Center is currently working on the study design and budget details.
- 29 Oct 2018 New trial record
- 22 Oct 2018 According to a Hemispherx Biopharma media release, the company in collaboration with the University of Nebraska Medical Center (UNMC) is planning this trial.